Yissum - Research Development Company of the Hebrew University

Novel Carbamoylphosphonates for the Regulation of Tumor Microenvironment

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster8

A novel family of compounds that target three types of cancer-related zinc enzymes: 1) matrix metalloproteinases (MMP2 and 9) involved in tumor metastasis dissemination, and 2) two tumor related carbonic anhydrases (CIs IX and XII) that regulate the pH in the tumors’ microenvironment 3) Autotaxin
Project ID : 6-2008-2122

Description of the technology

Categories

Cancer, metastasis, drug, zinc enzyme inhibitor

Development Stage

Drug at preclinical stage

Background

  • The process of cancer metastasis consists of a series of sequential events that requires deregulated proliferation and eventually distal dissemination involving detachment from the extracellular matrices and invasion of the surrounding normal tissue
  • Enzymes are critical for multiple processes during malignant progression and are hallmarks in tumor angiogenesis, local and distal invasion and cellular dissemination by acting as part of an extensive multidirectional network. Among them, matrix metalloproteinases occupy central nodes of this process. Localized proteolysis at the tumor-matrix interface signifies the transition from a benign state to a malignant one. Therefore the events in the microenvironment of the transformed cell play a critical role in the progression to malignancy.
  • The enhanced proliferative capacity of tumor cells, owing to the enzyme autotaxin, creates oxygen and nutrient deficient environment. The hypoxia condition initiates several enzymatic pathways including those of specific carbonic anhydrases, enzymes involved in the regulation of intra and extracellular pH, and therefore essential for the survival and proliferation of the cancer cells.

Our Innovation

A novel family of compounds that target three types of cancer-related extra-cellular zinc dependent enzymes:

  • matrix metalloproteinases (MMP2 and 9) involved in tumor metastasisdissemination, and
  • two tumour-related carbonic anhydrases (CAs 9 and 12) that regulate the pH in the microenvironment and
  • autotaxin (ATX) promoting tumor cell proliferation.
  • Our orally bioavailable novel compounds self-target only into the extracellular space where the zinc-dependent enzymes also operate. Being unable to enter the cells by crossing lipid cell-membranes due to their polar nature, there are no toxic side effects observed in the course of such joint anti-cancer action
  • The unique zinc binding group (ZBG) of the ionic carbamoylphosphonates (CPO) assures solubility in the extracellular fluid where the target enzymes operate.
  • The compounds are useful by once daily oral administration, they show no toxicity, including musculoskeletal side effects manifested by most other similar drug candidates.

Key Features

  • Oral activity in cancer metastasis models.
  • Water soluble
  • Non toxic
  • The ionic drugs concentrate in the extracellular fluid and do not cross cell membranes.
  • Enzyme selective – our compounds inhibit only the metalloenzymesCAs & MMPs, which operate in the extracellular fluid and are directly involved in the disease.

Development Milestones

  • Modifying molecules in order to reach second generation compounds with optimized potency, affinity, and specificity toward ATX, CAs & MMPs.

The Opportunity

  • The oncology market is the third largest drug market.
  • The global cancer market is predicted to grow at a CAGR exceeding 10%

Researcher Informationpharmacy.huji.ac.il/eng/staff_win.asp?id=35&type=2

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Amnon Hoffman
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Eli Breuer
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Reuven Reich
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.